{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-033543","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2022-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.312178+00:00","generated_at":"2026-06-21T13:20:35.039497+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Palisade Bio appoints Dr. Herbert Slade as Chief Medical Officer effective Nov 17, 2022","bullets":["Dr. Slade will serve as part-time consultant CMO with annual compensation of $240,000.","He had been consulting for the company since May 2022 and previously served as clinical advisor for LB1148.","Over 25 years of pharmaceutical/medical device leadership; previously CMO at Smith & Nephew, DFB Pharma, 3M Pharma.","No severance or termination benefits are provided in the consulting arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-033543","json":"https://secwatch.observer/filing/0001493152-22-033543.json","markdown":"https://secwatch.observer/filing/0001493152-22-033543.md","text":"https://secwatch.observer/filing/0001493152-22-033543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222033543/0001493152-22-033543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222033543/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:20:35.039497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2760a30b4b","claim":"Herbert B. Slade was appointed as chief medical officer at PALISADE BIO, INC..","evidence_excerpt":"On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222033543/0001493152-22-033543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chief medical officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}